Infliximab in paediatric inflammatory bowel disease
Pere Vilar1, Javier Martín de Carpi, Claudia E Acuña
1Paediatric Gastroenterology Section, Hospital Universitari Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.
Journal of Crohn'S & Colitis
|December 22, 2010
Summary
Infliximab is effective for pediatric Crohn
Area of Science:
- Pediatric Gastroenterology
- Immunology
- Inflammatory Bowel Disease
Background:
- Infliximab is utilized for pediatric Crohn's disease, particularly luminal and fistulous types unresponsive to standard therapies.
- Its application is expanding in refractory pediatric ulcerative colitis.
- Evidence suggests comparable efficacy and safety in pediatric versus adult populations.
Purpose of the Study:
- To evaluate the role and impact of infliximab in managing pediatric inflammatory bowel diseases (IBD).
- To explore the potential of early infliximab intervention to alter disease trajectory and reduce corticosteroid dependency.
- To assess infliximab's contribution to mucosal healing and normal development in pediatric IBD patients.
Main Methods:
- Review of existing literature and clinical data on infliximab use in pediatric IBD.
- Analysis of efficacy and safety profiles in comparison to adult data.
- Exploration of infliximab's mechanism as a bridging therapy.
Main Results:
- Infliximab demonstrates similar efficacy and safety in children and adults with IBD.
- Early use may reduce steroid requirements and modify the natural history of pediatric IBD.
- Mucosal healing observed with infliximab may support normal growth and sexual maturation.
Conclusions:
- Infliximab is a valuable therapeutic option for pediatric Crohn's disease and ulcerative colitis.
- Early infliximab treatment in pediatric IBD could improve outcomes, including reduced steroid use and enhanced development.
- Further research into early infliximab use is warranted to optimize pediatric IBD management.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...